SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: sellaslifesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2021 | $18.00 | Overweight | Cantor Fitzgerald |
Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00
RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
10-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
424B5 - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on Wednesday, May 21, 2025 at 8:20 am ET. A.G.P. Virtual Healthcare Company Showcase Details: Format: Fireside chat Date: Wednesday, May 21, 2025Time: 8:20 a.m. ETWebcast Link: Click Here About SELLAS Life Sciences Group, Inc.SELLAS is a late-stage clinical bioph
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient has been dosed in the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). "Building upon our promising Cohort 3 data, we are pleased to dose our first pediatric AML patient as part of the ongoing Phase 2 trial," said Dragan Cicic, MD, Chief Development Officer of SELLAS. "This milestone reflects
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients – – SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL) Xenograft Models – – Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Anticipated in 2025 – – $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises – NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDA
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in TP53 mutated Acute Myeloid Leukemia (AML) cells are being presented in a poster session at the American Association for Cancer Research (AACR) taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. Patients with TP53–mutated AML continue to face extremely poor outcomes, even with intensive chemotherapy or the addition of stem cell transplantation. Precl
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois. Poster presentation details: Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 P
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR - - Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a br
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009 (Tambiciclib) in r/r AML – Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – – Raised $25 Million in Gross Proceeds in a Registered Direct Offering in January 2025 – NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focus
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being discussed among oncology experts around the world. Recently, the New York Times put out a report asking big questions about cancer and its treatments, including about the impact of pollution (including microplastics) on cancer rates, genetic mutations, and inflammation. In the UK, The Guardian reported research showing a need for further studies into air pollution as lung cancer diagnoses are on the rise among never-smokers worldwide. As
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall Survival Not Reached Yet – 67% of Patients Still Alive - NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced data from Phase 2a trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). The trial, cond
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China National Ethics Committee Approval for GPS Phase 3 REGAL Study Received in Greece Preparations Underway to Activate Clinical Trial Sites and Enroll Patients in the REGAL Study in France, Germany and Greece by End of Second Quarter 2021 NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of in
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality. He joins the Company's executive leadership team and is responsible for developing and executing regulatory strategies. Elnatan has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology, and hematological diseases. His career spans over 25
NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the Company has appointed Robert Francomano as Chief Commercial Officer, effective immediately. Mr. Francomano brings significant and broad biopharmaceutical commercial leadership to SELLAS, including experience building and managing oncology product brands through all stages of commercialization, most recently as Chief Commercial Officer at Stemline Therapeutics until the completion and integration of its acquisition by
SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)
SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)